CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Regulation FD Disclosure
ITEM 7.01.REGULATION FD DISCLOSURE.

99.1

Press Release entitled "Chembio Diagnostics Reports Second Quarter 2017 Financial Results" dated August 9, 2017

99.2

Presentation entitled "Investor Presentation August 2017" dated August 9, 2017

99.3

Investor Fact Sheet posted to the company website dated August 9, 2017

CHEMBIO DIAGNOSTICS, INC. Exhibit
EX-99.1 2 ex99_1.htm EXHIBIT 99.1 PRESS RELEASE Exhibit 99.1 Chembio Diagnostics Reports Second Quarter 2017 Financial Results Conference Call and Webcast Today at 4:30 p.m. Eastern Time MEDFORD,…
To view the full exhibit click here

About CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI)

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company’s product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.